Strengthening10 Aug 2026
Reprogramming moves from markers to function
Two independent groups have now reported functional regeneration rather than clock changes alone. Private funding attention is following the shift.
Cellular reprogrammingMarkets
Where the science meets the market
LONGEFI maps scientific developments to the technologies, themes and companies they touch. We do not rate securities, forecast prices, or make recommendations.
Intelligence signals
A signal marks a change in the strength of evidence or commercial position of a theme. Signals may be scientific, clinical, regulatory, company, market or funding in nature.
Strengthening9 Aug 2026
Local delivery rescues the senolytic thesis
Durable ocular results validate the mechanism where delivery is contained. Read-through to systemic senolytics remains weak.
SenolyticsStrengthening7 Aug 2026
In vivo editing durability now measured in years
24-month stability lowers platform risk for any future preventive genetic intervention delivered to the liver.
Gene therapyWatch4 Aug 2026
NAD+ biomarker-to-benefit gap widens
Levels rise reliably; function does not follow in 12-week designs. Consumer claims are increasingly exposed.
NAD+Weakening26 Jul 2026
Clock endpoints rejected as standalone efficacy measures
Trial timelines and costs increase across clinical-stage geroscience. Diagnostics businesses are largely unaffected.
EpigeneticsWatch2 Aug 2026
mTOR restart carries prior pivotal failure
The strongest animal mechanism in the field still has no positive human clinical endpoint. Apply a raised evidence bar.
mTORStable31 Jul 2026
Measurement is where longevity revenue exists today
Large cohort evidence supports earlier metabolic screening. Therapeutic differentiation remains thin.
Metabolic healthPublic longevity companies
Tracked for scientific exposure. No market-data provider is connected: price, daily change and market cap are intentionally not shown.
| Ticker | Company | Technology | LONGEFI signal | |
|---|---|---|---|---|
| UBX | Unity Biotechnology | Senolytics | StableDurability data in line | |
| NTLA | Intellia Therapeutics | In vivo CRISPR gene editing | StrengtheningDurability extended | |
| BEAM | Beam Therapeutics | Base editing | StableProgramme on track | |
| ISM | Insilico Medicine | Generative AI drug discovery | StrengtheningPhase 2a readout | |
| RXRX | Recursion Pharmaceuticals | Phenomics + ML drug discovery | StablePlatform expansion | |
| CDXC | ChromaDex | Nicotinamide riboside (consumer NAD+) | WatchMixed trial endpoints | |
| VRMB | Veri Metabolic | Metabolic health measurement and therapeutics | StrengtheningPlatform revenue expanding | |
| ENLV | Enlivex Therapeutics Ltd. | Allogeneic macrophage-reprogramming cell therapy | — | |
| BIIB | Biogen Inc. | Antisense oligonucleotide (ASO) | — | |
| IONS | Ionis Pharmaceuticals, Inc. | Antisense oligonucleotide (ASO) | — | |
| DNLI | Denali Therapeutics Inc. | Oligonucleotide Transport Vehicle (OTV), blood-brain barrier delivery | — |
Listing here reflects scientific relevance only. It is not a recommendation, rating or solicitation to trade. Price, today’s change, 1-month change and market cap will appear here only once an objective market-data provider is connected.
Upcoming catalysts
Clinical readouts, regulatory decisions, trial milestones and scheduled company events will be listed here. LONGEFI does not estimate or invent catalyst dates, so nothing is shown until verified scheduled events are ingested.
Funding & deals
Funding rounds, licensing, partnerships, M&A and strategic investments are ordinary news events and will surface here from the news stream once the private-market feed is live.
Technologies
Current state of each tracked technology.
- Cellular reprogrammingPartial reprogramming
Animal-stage; first ocular INDs approaching.
- SenolyticsSenolytic small molecules
Human durability shown locally; systemic unsolved.
- Gene therapyIn vivo CRISPR
Multi-year human durability established.
- Gene therapyBase editing
Early human efficacy in monogenic disease.
- EpigeneticsEpigenetic clocks
Useful for enrichment, not for approval.
- Stem cellsiPSC manufacturing
Batch consistency reached registrational thresholds.
- mTORSelective TORC1 inhibition
Mechanism strong in animals, unproven in humans.
- NAD+NAD+ precursors
Biomarker reliable; functional benefit unproven.
- ImmunologyThymic regeneration
Pilot-stage only; heavily over-reported.
- Metabolic healthContinuous metabolic monitoring
Commercially validated measurement layer.
- AI drug discoveryGenerative chemistry
Producing candidates; attribution hard to verify.
- Gene therapyLNP delivery
Liver-biased; other tissues remain the bottleneck.
Trending themes
LONGEFI Attention is an editorial attention indicator, not a scientific probability and not a market rating. No authoritative calculation exists yet, so the values below are illustrative.
- Cellular healthAttentionMock92+6
Reprogramming and senescence work converging on function-level endpoints.
- Immune agingAttentionMock81+3
Cheap, objective endpoints are pulling trial activity toward immunology.
- Metabolic healthAttentionMock77-2
Strong epidemiology, crowded commercial field, thin therapeutic differentiation.
- Delivery platformsAttentionMock74+5
LNP and AAV durability data are the quiet precondition for everything else.
- AI discoveryAttentionMock69+4
First AI-originated assets reaching mid-stage trials in aging-adjacent indications.
- Biomarker validationAttentionMock58-7
Regulatory caution on clocks is repricing the value of biomarker-only stories.